Outpatient parenteral antimicrobial therapy: Recent developments and future prospects

Current Opinion in Investigational Drugs

Volumn 11, Issue 8, 2010, Pages 929-939

  Török, M Estee ^a   Chapman, Ann L N ^b   Lessing, M P Albert ^c   Sanderson, Frances ^d   Seaton, R Andrew ^e  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

AmBisome; caspofungin; dalbavancin; daptomycin; doripenem; ertapenem; omadacycline; OPAT; outpatient parenteral antimicrobial therapy; polymyxin B; teicoplanin; telavancin; tigecycline

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CEFTRIAXONE; CILASTATIN; CIPROFLOXACIN; CLINDAMYCIN; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; LINEZOLID; MOXIFLOXACIN; OMADACYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; PTK 0796; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTHROPATHY; BACTEREMIA; BACTERIAL INFECTION; BILIARY TRACT DISEASE; BLOOD CLOTTING DISORDER; BONE INFECTION; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCARDITIS; ESOPHAGUS CANDIDIASIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFECTION; INJECTION SITE REACTION; INVASIVE ASPERGILLOSIS; KIDNEY DISEASE; LEISHMANIASIS; LEUKOPENIA; LIVER INJURY; LOADING DRUG DOSE; LOW DRUG DOSE; LYME DISEASE; MYALGIA; MYCOSIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OSTEOMYELITIS; OUTPATIENT CARE; PELVIC INFLAMMATORY DISEASE; PERITONITIS; PHLEBITIS; PLEURISY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SURGICAL INFECTION; TASTE DISORDER; THROMBOCYTOSIS; TINNITUS; TYPHOID FEVER; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VESTIBULAR DISORDER; VIRUS INFECTION; VOMITING;

AMBULATORY CARE; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BETA-LACTAMS; DAPTOMYCIN; DOSAGE FORMS; HUMANS; INFUSIONS, PARENTERAL; TEICOPLANIN;

EID: 77955008531     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Rucker RW, Harrison GM: Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics (1974) 54(3): 358-360.
2. Tice AD: An office model of outpatient parenteral antibiotic therapy. Rev Infect Dis (1991) 13(Suppl 2):S184-S188.
3. Tice AD: Once-daily ceftriaxone outpatient therapy in adults with infections. Chemotherapy (1991) 37(Suppl 3):7-10.
4. Tice AD: Outpatient parenteral antibiotic therapy. Management of serious infections. Part ii: Amenable infections and modelsfor delivery. Osteomyelitis. Hosp Pract (Off Ed) (1993) 28 (Suppl 2):36-39; Discussion 60-131
5. Tice AD: Outpatient parenteral antibiotic therapy. Management of serious infections. Part i: Medical, socioeconomic, and legal issues. The team concept. Hosp Pract (Off Ed) (1993) 28(Suppl 1):6-10.
6. Tice AD: Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis (1995) 14(7):655-661
7. Tice AD: The importance of teamwork for outpatient parenteral antibiotic therapy. Int J Antimicrob Agents (1995) 5(1):13-17.
8. Tice A: Outpatient parenteral antimicrobial therapy as an alternative to hospitalization. Int J Clin Pract Suppl (1998) 95:4-8.
9. Tice AD: Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am (1998) 12(4):903-919.
10. Tice AD: Outpatient parenteral antibiotic therapy for fever and neutropenia. Infect Dis Clin North Am (1998) 12(4):963-977.
11. Tice AD: Safety of outpatient parenteral antimicrobial therapy for endocarditis. Clin Infect Dis (2002) 34(3):419-420.
12. Tice AD, Hoaglund PA, Shoultz DA: Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med (2003) 114(9):723-728.
13. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN: Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis (2004) 38(12):1651-1672.
14. Chary A, Tice AD, Martinelli LP, Liedtke LA, Plantenga MS, Strausbaugh LJ: Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: Results of an emerging infections network survey. Clin Infect Dis (2006) 43(10):1290-1295.
15. White HA, Davis JS, Kittler P, Currie BJ: Outpatient parenteral antimicrobial therapy-treated bone and joint infections in a tropical setting. Intern Med J (2009):doi:10.1111/j.1445-5994.2009.02136.x.
16. Nathwani D: The management of skin and soft tissue infections: Outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy (2001) 47(Suppl 1):17-23.
17. Esposito S, Noviello S, Leone S, Tice A, Seibold G, Nathwani D, Scaglione F: Outpatient parenteral antibiotic therapy (OPAT) in different countries: A comparison. Int J Antimicrob Agents (2004) 24(5):473-478.
18. Seaton RA, Bell E, Gourlay Y, Semple L: Nurse-led management of uncomplicated cellulitis in the community: Evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother (2005) 55(5):764-767.
19. Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, Byren I: Outpatient parenteral antimicrobial therapy (OPAT): Is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother (2007) 60(2):356-362.
20. Nathwani D: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. J Antimicrob Chemother (2009) 64(3):447-453.
21. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD: Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): A UK perspective. J Antimicrob Chemother (2009) 64(6):1316-1324.
22. Stamboulian D: Outpatient treatment of endocarditis in a clinic-based program in argentina. Eur J Clin Microbiol Infect Dis (1995) 14(7):648-654.
23. Lopardo G: Management of endocarditis: Outpatient parenteral antibiotic treatment in argentina. Chemotherapy (2001) 47(Suppl 1):24-32.
24. Esposito S, Ianniello F, Noviello S, Leone S, Ascione T, Tice A, Maiello A, de Lalla F, Girmenia C, Marranconi F, Serrentino G et al: [Outpatient parenteral antibiotic therapy (OPAT): The Italian registry]. Infez Med (2002) 10(3):169-175.
25. Howden BP, Grayson ML: 5: Hospital-in-the-home treatment of infectious diseases. Med J Aust (2002) 176(9):440-445.
26. Fisher DA, Kurup A, Lye D, Tambyah PA, Sulaiman Z, Poon EY, Lee W, Kaur V, Lim PL: Outpatient parenteral antibiotic therapy in singapore. Int J Antimicrob Agents (2006) 28(6):545-550.
27. Yong C, Fisher DA, Sklar GE, Li SC: A cost analysis of outpatient parenteral antibiotic therapy (OPAT): An asian perspective. Int J Antimicrob Agents (2009) 33(1):46-51.
28. Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ: Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A canadian teaching hospital and ministry of health perspective. Pharmacoeconomics (2000) 18(5):451-457.
29. Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E: Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy (2002) 22(2 Pt 2):63S-70S.
30. Wiselka MJ, Nicholson KG: Outpatient parenteral antimicrobial therapy: Experience in a large teaching hospital. J Infect (1997) 35(1):73-76.
31. Nathwani D, Barlow GD, Ajdukiewicz K, Gray K, Morrison J, Clift B, France AJ, Davey P: Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother (2003) 51(2):391-396.
32. Goodfellow AF, Wai AO, Frighetto L, Marra CA, Ferreira BM, Chase ML, Nicol RE, Leong CA, Tomlinson S, Jewesson PJ: Quality-of-life assessment in an outpatient parenteral antibiotic program. Ann Pharmacother (2002) 36(12):1851-1855.
33. Nathwani DJ: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. Antimicrob Chemother (2009) 64(3):447-453.
34. Wenisch C, Etzersdorfer E, Breyer S, Graninger W: Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea. Clin Investig (1994) 72(11):922-924.
35. Lazzarini L, Tramarin A, Bragagnolo L, Tositti G, Manfrin V, de LF: Three-times weekly teicoplanin in the outpatient treatment of acute methicillin-resistant staphylococcal osteomyelitis: A pilot study. J Chemother (2002) 14(1):71-75.
36. Pensotti C, Nacinovich F, Vidiella G, Carbone E, Marin M, Di Stefano C, Stamboulian D: Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients. Medicina (B Aires) (2002) 62(Suppl 2):40-47.
37. Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH: Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother (2009) 64(1):181-187.
38. Seaton RA, Bell E, Bezlyak V, Weir CJ: Factors associated with outcome and length of parenteral therapy in outpatient parenteral antibiotic therapy-treated patients with skin and soft tissue infections. European Congress on Clinical Microbiology and Infectious Diseases, Vienna, Austria (2010) 20:Abs P-1333.
39. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA: Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother (2003) 47(5):1689-1693.
40. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis (2004) 38(12):1673-1681.
41. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH et al: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 355(7):653-665.
42. Crompton JA, North DS, McConnell SA, Lamp KC: Safety and efficacy of daptomycin in the treatment of osteomyelitis: Results from the core registry. J Chemother (2009) 21(4):414-420.
43. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC: Safety and clinical outcomes when utilizing high-dose (or =8 mg/kg) daptomycin therapy. Ann Pharmacother (2009) 43(7):1211-1219.
44. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ: A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int J Clin Pract (2008) 62(9):1455 1464.
45. Entenza JM, Giddey M, Vouillamoz J, Moreillon P: In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int J Antimicrob Agents (2010) 35(5):451-456.
46. Martone WJ, Lindfield KC, Katz DE: Outpatient parenteral antibiotic therapy with daptomycin: Insights from a patient registry. Int J Clin Pract (2008) 62(8):1183-1187.
47. Dohmen P, Guleri A, Petrosillo N, Utili R, Gonzàlez Sanz V, Seaton RA, Gonzàlez-Ramallo VJ, Hetzer R, Heep M, Thurston HJ, Chaves RL: Daptomycin for the treatement of infective endocarditis: Results from the European Cubicin Outcomes Registry and Experience (EUCORE). European Congress on Clinical Microbiology and Infectious Diseases, Vienna, Austria (2010) 20:Abs O511.
48. Seaton RA, Gargalianos-Kakolyris P, Malizos K, Romero-Candau F, Carretta A, Hernàndez-Quero J, Militz M, Reus Bauls S, Riccio G, Heep M, Thurston HJ et al: Evaluation of safety and tolerability of daptomycin in the treatment of osteomyelitis: Results from a European Registry. European Congress on Clinical Microbiology and Infectious Diseases, Vienna, Austria (2010) 20:Abs O513.
49. Seaton RA, Macconnachie AA: Experience with daptomycin in an infectious diseases service over 1 year: Utility in an outpatient parenteral antibiotic programme. Int J Antimicrob Agents (2008) 31(5):492-497.
50. van Anglen LJ: Comparison of outpatient antibiotic therapy use of daptomycin, linezolid, quinupristin/dalfopristin, tigecycline and vancomycin in physician-operated infusion centers (POICS). ICAAC (2008):Abs K-380.
51. Tice AD: Ertapenem: A new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother (2004) 53(Suppl 2):ii83-ii86.
52. Graham DR, Lucasti C, Malafaia O, Nichols RL, Holtom P, Perez NQ, McAdams A, Woods GL, Ceesay TP, Gesser R: Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis (2002) 34(11):1460-1468.
53. Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, Gesser RM: A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology (2002) 60(1):16-22.
54. Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: Results of a prospective, randomized, double-blind multicenter study. Antimicro Agents Chemother (2002) 46(9):2895-2900.
55. Yellin AE, Hassett JM, Fernandez A, Geib J, Adeyi B, Woods GL, Teppler H: Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents (2002) 20(3):165-173.
56. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V et al: Ertapenem versus piperacillin/ tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial. Ann Surg (2003) 237(2):235-245.
57. Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA: Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intraabdominal infections in hospitalized adults. Surg Infect (Larchmt) (2007) 8(1):15-28.
58. Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, Teppler H: Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: A prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol (2003) 11(1):27-37.
59. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A: A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis (2002) 34(8):1076-1083.
60. Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, Isaacs R: A prospective, randomized, doubleblind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther (2002) 24(11): 1770-1785.
61. Yakovlev SV, Stratchounski LS, Woods GL, Adeyi B, McCarroll KA, Ginanni JA, Friedland IR, Wood CA, DiNubile MJ: Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis (2006) 25(10):633-641.
62. Bassetti M, Righi E, Fasce R, Molinari MP, Rosso R, Di Biagio A, Mussap M, Pallavicini FB, Viscoli C: Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum ?-lactamase- producing organisms in an intensive care unit. J Antimicrob Chemother (2007) 60(2): 433-435.
63. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA: Ertapenem versus piperacillin/tazobactam for diabetic foot infections (sidestep): Prospective, randomised, controlled, double-blinded, multicentre trial. Lancet (2005) 366(9498):1695-1703.
64. Teng CP, Chen HH, Chan J, Lye DC: Ertapenem for the treatment of extended-spectrum ?-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents (2007) 30(4): 356-359.
65. Bazaz R, Chapman AL, Winstanley TG: Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-?-lactamaseproducing Gram-negative organisms. J Antimicrob Chemother (2010) 65(7):1510-1513.
66. An MM, Zou Z, Shen H, Zhang JD, Chen ML, Liu P, Wang R, Jiang YY: Ertapenem versus piperacillin/ tazobactam for the treatment of complicated infections: A meta-analysis of randomized controlled trials. BMC Infect Dis (2009) 9:193.
67. Gesser RM, McCarroll KA, Woods GL: Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect (2004) 48(1):32-38.
68. Paterson DL, Depestel DD: Doripenem. Clin Infect Dis (2009) 49(2):291-298.
69. Matthews SJ, Lancaster JW: Doripenem monohydrate, a broadspectrum carbapenem antibiotic. Clin Ther (2009) 31(1):42-63.
70. Noskin GA: Tigecycline: A new glycylcycline for treatment of serious infections. Clin Infect Dis (2005) 41(Suppl 5): S303-S314.
71. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis (2005) 41(Suppl 5):S341-353.
72. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis (2005) 41(Suppl 5):S354-367.
73. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R: Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis (2008) 61(3):329-338.
74. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: Results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis (2009) 63(1):52-61.
75. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N et al: Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother (2008) 62(Suppl 1):i17-i28.
76. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico, et al: A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother (2008) 62(Suppl 1):i29-i40.
77. Zavascki AP, Goldani LZ, Li J, Nation RL: Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother (2007) 60(6):1206-1215.
78. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J: Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis (2008) 47(10):1298-1304.
79. Moen MD, Lyseng-Williamson KA, Scott LJ: Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs (2009) 69(3):361-392.
80. Simon A, Bode U, Maul M, Fleischhack G: Liposomal amphotericin B can safely be administered in paediatric outpatients with cancer for the primary or secondary prevention of invasive aspergillosis. Acta Haematol (2007) 118(2):68-69.
81. Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E: Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol (2007) 56(4):612-616.
82. Brown M, Noursadeghi M, Boyle J, Davidson RN: Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol (2005) 153(1):203-205.
83. di Martino L, Davidson RN, Giacchino R, Scotti S, Raimondi F, Castagnola E, Tasso L, Cascio A, Gradoni L, Gramiccia M, Pettoello-Mantovani M et al: Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr (1997) 131(2):271-277.
84. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: The newest class of antifungals. Ann Pharmacother (2009) 43(10):1647-1657.
85. Saravolatz LD, Stein GE, Johnson LB: Telavancin: A novel lipoglycopeptide. Clin Infect Dis (2009) 49(12):1908-1914.
86. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL et al: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis (2008) 46(11): 1683-1693.
87. Rubinstein E, Corey GR, Boucher HW et al: Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: The attain studies. ICAAC (2008):Abs K-529.
88. Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C: Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis (2008) 46(4):577-583.
89. Lin G, Credito K, Ednie LM, Appelbaum PC: Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother (2005) 49(2):770-772.
90. Lin G, Smith K, Ednie LM, Appelbaum PC: Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob Agents Chemother (2005) 49(12):5182-5184.
91. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN: Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother (2009) 53(3):1260-1263.
92. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T: Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis (2003) 37(10):1298-1303.
93. J auregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis (2005) 41(10):1407-1415.
94. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, Goldstein B, Henkel T, Seltzer E: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis (2005) 40(3):374-380.
95. Technology platforms: The tetracycline program: PARATEK Pharmaceuticals Inc, Boston, MA, USA (2010). www.paratekpharm. com/pt-tet-inhib.html
96. Novartis AG: Novartis gains exclusive worldwide rights to PTK 0796, in phase III study as potential first-in-class iv and oral broad-spectrum antibiotic. Press Release (2009): October 8. www.novartis.com/newsroom/media- releases/en/2009/1346369.shtml
97. Esposito S, Leone S, Noviello S, Ianniello F, Russo M, Foti G, Carpentieri MS, Cellesi C, Zanelli G, Cellini A, Girmenia C et al: Outpatient parenteral antibiotic therapy in the elderly: An Italian observational multicenter study. J Chemother (2009) 21(2):193-198.
98. Esposito S, Leone S, Noviello S, Ianniello F, Fiore M, Russo M, Foti G, Carpentieri MS, Cellesi C, Zanelli G, Cellini A et al: Outpatient parenteral antibiotic therapy for bone and joint infections: An Italian multicenter study. J Chemother (2007) 19(4):417-422.
99. Wynn M, Dalovisio JR, Tice AD, Jiang X: Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J (2005) 98(6):590-595.
100. Tice A: The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: Data from the outpatient parenteral antimicrobial therapy outcomes registries. Chemotherapy (2001) 47(Suppl 1):5-16.
101. Poretz DM: Outpatient parenteral antibiotic therapy. Int J Antimicrob Agents (1995) 5(1):9-12.
102. Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH: Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother (2009) 64(1):181-187.